Treatment with the immunomodulator AM3 improves the health-related quality of life of patients with COPD
- PMID: 15821197
- DOI: 10.1378/chest.127.4.1212
Treatment with the immunomodulator AM3 improves the health-related quality of life of patients with COPD
Abstract
Background: COPD has a severe impact on patient quality of life. AM3 is an orally effective immunomodulator that can normalize the defective antimicrobial functions of the immune system effector cells of COPD patients.
Objectives: We analyzed the effect of AM3 on exacerbation frequency and health-related quality of life (HRQL) of COPD patients with moderate disease.
Design: A randomized, double-blind, placebo-controlled trial.
Setting: Outpatient departments of 21 hospitals.
Methods: A total of 253 COPD patients with a mean age of 67.7 years (SD, 8.1 years) and mean FEV(1) percentage of predicted of 49.6% (SD, 10.2%) were evaluated. Patients received (orally) either 3 g/d AM3 or a matched placebo for 180 consecutive days. Patient quality of life was measured using the St. George's Respiratory Questionnaire (SGRQ).
Results: There were no differences in the exacerbation frequency of the two groups (0.82 episodes per patient in the AM3 arm vs 0.84 in the placebo arm), and 55.3% of patients were exacerbation free in the AM3 arm compared to 48.8% in the placebo arm (p = 0.11). At the end of treatment, quality of life was significantly better in the AM3 arm than in the placebo arm (SGRQ total score, 32.9; SD, 16.4, compared to 37.5; SD, 17.5 [p < 0.05]: activity score, 47.5; SD, 22.4, compared to 54.6; SD, 20.5 [p < 0.05]). The improvements in total SGRQ scores were 8.9 U (SD, 13.4 U) in the AM3 arm and 5.6 U (SD, 15.9 U) in the placebo arm (p = 0.076). Improvements on the symptoms subscale were 15.9 U (SD, 20.7 U) for the AM3 arm and 10.2 U (SD, 21.3 U) for the placebo arm (p < 0.05). Both AM3 and the placebo were clinically, biochemically, and hematologically well tolerated.
Conclusions: AM3 is a safe, easily tolerated, effective treatment that improves the quality of life of COPD patients as measured by SGRQ scores. This effect was observed with no significant reduction in the frequency of exacerbations.
Similar articles
-
Treatment with AM3 restores defective T-cell function in COPD patients.Chest. 2006 Mar;129(3):527-35. doi: 10.1378/chest.129.3.527. Chest. 2006. PMID: 16537848 Clinical Trial.
-
[Effect of AM3 on health-related quality of life in patients with chronic obstructive pulmonary disease belonging to risk groups].Med Clin (Barc). 2008 May 17;130(18):688-92. doi: 10.1157/13120769. Med Clin (Barc). 2008. PMID: 18501139 Clinical Trial. Spanish.
-
Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.Clin Ther. 2007 Feb;29(2):261-78. doi: 10.1016/j.clinthera.2007.02.009. Clin Ther. 2007. PMID: 17472819 Clinical Trial.
-
[Effect of immunomodulator AM3 on the exacerbations in patients with chronic bronchitis: a systematic review of controlled trials].Rev Clin Esp. 2004 Sep;204(9):466-71. doi: 10.1157/13065976. Rev Clin Esp. 2004. PMID: 15388020 Spanish.
-
Indacaterol therapy in patients with COPD not receiving other maintenance treatment.Respir Med. 2012 Dec;106(12):1706-14. doi: 10.1016/j.rmed.2012.08.022. Epub 2012 Sep 29. Respir Med. 2012. PMID: 23031496 Review.
Cited by
-
Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease.Cochrane Database Syst Rev. 2022 Nov 14;11(11):CD013343. doi: 10.1002/14651858.CD013343.pub2. Cochrane Database Syst Rev. 2022. PMID: 36373977 Free PMC article.
-
Exacerbations, hospital admissions and impaired health status in chronic obstructive pulmonary disease.Qual Life Res. 2006 Apr;15(3):471-80. doi: 10.1007/s11136-005-3215-y. Qual Life Res. 2006. PMID: 16547786
-
COPD exacerbations. 4: Prevention.Thorax. 2006 May;61(5):440-7. doi: 10.1136/thx.2005.041848. Thorax. 2006. PMID: 16648352 Free PMC article. Review.
-
Roles of Myeloid and Lymphoid Cells in the Pathogenesis of Chronic Obstructive Pulmonary Disease.Front Immunol. 2018 Jun 21;9:1431. doi: 10.3389/fimmu.2018.01431. eCollection 2018. Front Immunol. 2018. PMID: 29977245 Free PMC article. Review.
-
An empirical comparison of the WHOQOL-BREF and the SGRQ among patients with COPD.Qual Life Res. 2008 Jun;17(5):793-800. doi: 10.1007/s11136-008-9326-5. Epub 2008 May 24. Qual Life Res. 2008. PMID: 18500580 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical